Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease
Fig 2
Mortality risk in patients with CVD and hypertension—Advanced disease.
Forrest plots of univariate and multivariate analysis for mortality risk for the given clinical characteristics of patients who presented in the complicated phase (n = 620) (A) and those who presented in the critical phase (n = 194) (B).